📣 MEET THE CONFIRMED FACULTY OF #ESHCLL2026! 4th Translational Research Conference on Chronic Lymphocytic Leukaemia March 5–7, 2026 / Stockholm, Sweden More information ➡️ https://t.co/yyuD5rfxm7 Chairs : Jennifer Brown Paolo Ghia, @HallekMichael #ESHCONFERENCES #CLLsm #Lmsm

Congratulations to Dr. Jennifer Brown who was honored today with the @SocietyofHemOnc Keating Outstanding Achievement Award for her CLL pioneering work!! #SOHO25 #cllsm

We've had a fantastic first day of interviews at #iwCLL2025!🩸🌟 One of our highlights was catching up with @DanilovLab of @cityofhope to learn about the emerging promise of targeted protein degraders in CLL. Coming soon to https://t.co/O9p0vDBZp4!🎥 #CLLsm #Leusm @iwCLL

👉👉Important analysis from ERIC group in CLL (published in Leukemia) Time-to-first-Treatment (TTFT) for most somatic mutations is highly dependent on IGHV status 👉TP53ab (mut and/or del17p) with IGHV-M: 10+ yr TTFT !!! #leusm #CLLsm https://t.co/Y0FmSgipSP

In an interview from #iwCLL2025, Talha Munir discusses findings from the FLAIR trial comparing an MRD-guided ibrutinib-venetoclax strategy to ibrutinib or FCR for previously untreated CLL. Watch here: 👉 https://t.co/8vIaxavc0Q 👈 #CLLsm #Leusm #Leukemia #HemOnc @iwCLL

Acute leukemia experts from @fredhutch @uwmedicine are here! @RyanCassaday, Dr. Jacob Appelbaum, and Dr. Francesco Mazziotta shared updates on myeloid malignancies and ALL at #SeattleCT25 today. Follow for more! #Immunotherapy #ALL #leusm #lymsm #CLLsm #hemepath #MedX #MedTwitter

Provocative murine data suggesting combination of CAR-T and bispecifics may be curative 🐭 #EHA24 #cllsm

Dr. Furman making sense of ibrutinib discontinuation in #CLLsm during #GDUHEM. ⁦@GreatDebatesCME⁩

Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸 Watch our interview with @brittengordon of @OhioState from #iwCLL2025: 🎥 https://t.co/GKRNNGfIZZ #CLLsm #Leusm #Leukemia @iwCLL

Richter’s Transformation is such a terrible complication of CLL and unmet need. Thankfully we know much more now about the underlying biology. Dr. Erin Parry reviewing the newest findings at #iwCLL23 #iwCLL2023 #CLLsm

📣#ESHCLL2026: PRELIMINARY SCIENTIFIC PROGRAMME NOW LIVE! ➡️ https://t.co/yyuD5rfxm7 4th Translational Research Conference on Chronic Lymphocytic Leukaemia March 5–7, 2026 / Stockholm, Sweden Chairs : Jennifer Brown Paolo Ghia, @HallekMichael #ESHCONFERENCES #CLLsm #Lmsm

AMPLIFY trial in 1L CLL AV vs AVO vs FCR/BR in TP53wt CLL Improved PFS and OS with AV vs chemo AVO saw lots of covid deaths AVO marginal PFS - O probably not worth tox/time/cost even outside a pandemic 10% of pts withdrew from chemo arm after randomisation… #ASH24 #CLLsm

Monoclonal B-cell Lymphocytosis (MBL) to CLL [6/2/25] Woyach #ASCO25 #CLLsm CLL-IPI in MBL

We've just kicked off our second day at #iwCLL2025!🩸😁 It was great to hear from @ChrisPepper64 of @BSMSMedSchool, who shared insight into the development of novel strategies targeting the NF-κB signaling pathway in CLL, including a first-in-class PROTAC. #CLLsm #Leusm

Beautiful CLL genetics work presented by Dr. Ian Marquez-Lopez (Campo’s lab) at #EHA2025 showing that CLL is characterized, in a fraction of patients, by the expansion of multiple clones with distinct molecular features. These clones seem arise decades earlier in life #CLLsm

Good early data (@ 1 yr) of pirto+ven+obin in untreated CLL Benefit in that very few admissions required for TLS monitoring Good early efficacy data (see MRD comparison on conclusions slide) but the key will be the durability & absence of dead kinase mutations #ASH24 #CLLsm

📣 DISCOVER THE LEARNING OBJECTIVES OF #ESHCLL2026! 4th Translational Research Conference on Chronic Lymphocytic Leukaemia March 5–7, 2026 / Stockholm, Sweden Chairs : Jennifer Brown Paolo Ghia @HallekMichael More information➡️ https://t.co/yyuD5rfxm7 #ESHCONFERENCES #CLLsm #Lmsm

#SOHO25 #CLLsm #leusm Next Questions: Chronic Lymphocytic Leukemia | Alessandra Tedeschi, MD | Niguarda Cancer Center, Milan, Italy

Not long to go now until we head to #iwCLL2025 to delve into cutting‑edge CLL developments with leading experts in the field!🩸 Can't make it? Not to worry! We'll be bringing you all the latest updates here and on https://t.co/O9p0vDBrzw.🎥🎤 #CLLsm #Leusm #HemOnc @iwCLL